Moderna Stock Wipes Out $14 Billion as MRNAon Crashes 30% From Record

Moderna shares plunged one day after their historic 177% rally, erasing approximately $14.2 billion from the biotechnology company’s market value as investors reassessed the valuation created by its cancer-treatment breakthrough.

MRNA traded near $138.89 at 10:31 a.m. ET on Thursday, down 20.35% from Wednesday’s closing price of $174.38. The stock fell as low as $136.35 during the session.

Based on Moderna’s approximately 399.24 million outstanding shares, the decline reduced its implied market capitalization from about $69.62 billion to $55.45 billion.

The reversal followed an extraordinary session in which Moderna stock surged 177%, climbing from Tuesday’s $62.96 close to $174.38 on Wednesday. It reached an intraday high of $176.66.

MRNAon Falls From $193 to $136

The volatility was even more dramatic in the tokenized market.

Moderna’s Ondo tokenized stock, MRNAon, reached an all-time high of $193.43 before falling to $136.20—a peak-to-trough decline of approximately 29.6%.

At the available snapshot, MRNAon traded near $139.84, placing it 27.7% below its record. The token had approximately $567,000 in 24-hour trading volume and a reported market capitalization of around $358,000.

That token-market-cap figure represents the value of the circulating MRNAon supply. It should not be confused with Moderna’s corporate market capitalization.

The widely circulated $62-to-$195-to-$136 price sequence therefore combines two different instruments. The $62.96 starting point was Moderna’s Nasdaq closing price, while the higher $193.43 peak and $136.20 low were recorded by MRNAon.

The pullback also coincided with MEXC listing MRNAON/USDT for spot trading at 09:00 UTC on August 20. The listing expanded the venues available to tokenized-stock traders during an exceptionally volatile period.

Moderna’s Rally Exceeded New Wall Street Targets

No new clinical setback was announced before Thursday’s decline. The reversal instead appears to reflect profit-taking and concerns that Wednesday’s rally pushed Moderna beyond even the most optimistic updated analyst valuations.

UBS raised its Moderna target to $150 while maintaining a Neutral-equivalent rating. Bank of America increased its target to $170 and upgraded the stock to Neutral.

Goldman Sachs lifted its target to $120 while retaining a Neutral rating, and Morgan Stanley increased its forecast to $89 while maintaining an Equal Weight recommendation.

Moderna’s Wednesday closing price of $174.38 exceeded all four targets, including Bank of America’s Street-high $170 forecast. That valuation gap gave investors a reason to secure profits after the stock nearly tripled in one session.

Even after Thursday’s decline, MRNA remained above the latest targets from UBS, Goldman Sachs and Morgan Stanley at the time of reporting. Google Finance showed an average analyst target of approximately $82.62, although estimates varied widely.

Detailed Phase 3 Results Remain Unreleased

The underlying clinical development remains significant.

Moderna and Merck said their Phase 3 INTerpath-001 trial met its primary recurrence free survival endpoint and a key secondary endpoint measuring distant metastasis-free survival.

The trial enrolled 1,137 patients with surgically removed, high-risk stage IIB-IV melanoma. It compared Keytruda alone with Keytruda plus Moderna’s personalized mRNA treatment, intismeran autogene.

Intismeran is individually manufactured using mutations identified in each patient’s tumor. The treatment is designed to train the immune system to recognize and attack cancer cells carrying those mutations.

However, Moderna and Merck released only topline Phase 3 findings. They have not disclosed hazard ratios, absolute recurrence rates or the complete numerical efficacy results.

The study will also continue evaluating overall survival. Detailed results are expected to be presented at a medical conference and discussed with regulators.

What Comes Next for MRNA and MRNAon?

Moderna’s decline represents a valuation reset following an unusually aggressive rally—not evidence that its experimental cancer treatment has failed.

At $138.89, MRNA remained approximately 121% above its August 18 closing price. MRNAon was still up about 129% over seven days despite trading nearly 28% below its record high.

The next major catalyst will be the complete Phase 3 dataset, followed by regulatory discussions and clarity regarding a potential approval timeline.

Until those details arrive, MRNA and MRNAon could remain highly volatile. Wednesday’s rally priced in substantial commercial expectations before investors received the trial’s complete numerical results.